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AntipsychoticsStudies of patients with Parkinson’s disease receiving dopamimetics report conﬂicting evidence for early
learning of probabilistic cue–outcome associations that elicits frontal–striatal activity. Previous studies of
probabilistic association learning in patients with schizophrenia administered antipsychotics have displayed
conﬂicting evidence for normal and abnormal learning. The role of dopaminergic treatment (dopamimetic
versus dopamine antagonistic) effects on probabilistic association learning in these diseases that directly impact
the dopamine system is not fully understood. The current study examined the effects of dopaminergic therapies
on probabilistic association learning in 13 patients with schizophrenia and 8 patients with Parkinson’s disease
under two conditions: after withdrawal from dopaminergic treatment and following administration of appropri-
ate dopaminergic treatment. Medication order was counterbalanced in both groups. Patients with Parkinson’s
disease failed to demonstrate any signiﬁcant improvement over 150 trials, under both conditions (receiving or
withdrawn from dopamimetics). Patients with schizophrenia withdrawn from antipsychotics displayed signiﬁ-
cant improvement during later trials only. These results demonstrate an effect of dopamine (DA) signaling on
probabilistic association learning in that: (1) dopamine replacement therapy in Parkinson’s disease is insufﬁcient
to signiﬁcantly improve probabilistic association learning and (2) DA receptor blockade impairs and removal of
DA receptor blockade signiﬁcantly improves frontal–striatal-dependent probabilistic association learning in
schizophrenia, which is a novel ﬁnding and is opposite to the effects shown following removal of DA receptor
blockade on other cognitive domains reported previously.
Crown Copyright © 2013 Published by Elsevier B.V.Open access under CC BY-NC-SA license. 1. Introduction
Animal studies show that the striatum is essential for habit learning
(Divac et al., 1967; Packard et al., 1989; McDonald and White, 1993;
Aosaki et al., 1994). Human studies demonstrate that the caudate nucleus
is associated with probabilistic association learning (PAL). Functionalisease; YC, Young Control; EC,
iversity of New South Wales,
NSW, 2031Australia. Tel.: +61
kert).
South Wales and Neuroscience
ent, Johns Hopkins University
er Hillside Hospital, Glen Oaks,
ier B.V. Open access under CC BY-NC-Sneuroimaging studies of healthy adults show the concurrent activation
of frontal–striatal circuitry during PAL (Poldrack et al., 1999, 2001; Fera
et al., 2005). Huntington’s disease, characterized by cell loss in the cau-
date nucleus (Vonsattel et al., 1985), is associated with acquisition rate
(improvement over time) impairment during PAL (Knowlton et al.,
1996a).
Parkinson’s disease (PD), characterized by neuronal loss in the
substantia nigra resulting in depletion of dopamine projections to
the striatum (Hornykiewicz, 1966), is associated with acquisition
rate deﬁcits during early trials of PAL (Knowlton et al., 1996b; Sage
et al., 2003; Shohamy et al., 2004a). Other studies of patients with
PD receiving dopamimetic medication show “normal” learning during
early trials (Moody et al., 2004; Shohamy et al., 2004b; Shohamy et
al., 2009), although these studies either matched performance or
used easier probability schedules. Overall, patients with PD display
impaired PAL for which dopamimetics fail to fully normalize perfor-
mance or acquisition.
In schizophrenia (SC), there is indirect evidence for increased
striatal dopamine activity (Pilowsky et al., 1994; Laruelle et al., 1996)
and administration of antipsychotics act as dopamine D2 receptor an-
tagonists, although antipsychotics also bind other receptors such as
serotonin (Kapur and Seeman, 2001), producing symptom reduction.A license. 
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PAL acquisition rate in conjunction with impaired overall performance
(cumulative percent correct across all trials) (Weickert et al., 2002;
Keri et al., 2005; Horan et al., 2008; Weickert et al., 2009). However,
one study has shown preserved PAL acquisition rate and overall perfor-
mance (Keri et al., 2000) while others (Foerde et al., 2008; Weickert et
al., 2010) have shown impaired performance and acquisition in SC.
Given that the majority of studies have demonstrated impaired overall
performance during PAL in patients with SC receiving antipsychotics,
dopamine receptor blockade (reducing dopamine binding) may nega-
tively inﬂuence PAL.
The present study assessed the effect of a putative increase of dopa-
mine receptor signaling associated with antipsychotic withdrawal in SC
and a putative decrease of dopamine receptor signaling in patients with
PD withdrawn from dopamimetics using a PAL test at two time points
(once during dopaminergic treatment and once following withdrawal)
with a counterbalanced design. We predicted that people with PD will
display greater PAL impairment following removal of dopamimetics
relative to dopamimetic administration, while people with SC will dis-
play improved PAL following antipsychotic withdrawal relative to anti-
psychotic administration. Assessing these two patient groups on and off
their respective dopaminergic treatments will provide novel evidence
for the role of dopamine signaling on PAL.
2. Materials and methods
2.1. Participants
Thirteen patients with SC (9 males) participated in this study. Two
board-certiﬁed psychiatrists concurred on diagnosis by Structured Clinical
Interview for the Diagnostic and Statistical Manual, Fourth Edition without
knowledge of participant’s PAL performance. The frequency of diag-
nostic subtypes was as follows: 7 undifferentiated, 3 paranoid, and 3
schizoaffective. Patientswho received concurrent axis I psychiatric diag-
noses other than SC, or having a history of current substance abuse,
head injuries with loss of consciousness, seizures, central nervous
system infection, diabetes, or hypertension were excluded. Eight PD
patients (7males) recruited from theNINDS Experimental Therapeutics
Branch Parkinson’s clinic and the surrounding community also
participated.
Thirteen healthy young (9 males) and 10 elderly (5 males) adults
recruited through the National Institutes of Health Normal Volunteer
Ofﬁce also participated. Healthy young and older adults with a history
of psychiatric disorders, current substance abuse, head injuries with
loss of consciousness, seizures, central nervous system infection,
diabetes, or hypertension were excluded. All participants provided
informed written consent prior to participation. The Institutional
Review Board of the National Institute of Mental Health approved
this study.
2.2. Psychotic symptoms and Parkinson’s disease severity
Psychotic symptom severity was assessed weekly in patients with
SC using the Positive and Negative Syndrome Scale (PANSS) (Kay et
al., 1987) by nursing staff trained and experienced in administration
and scoring. The assessment closest to the PAL test was used to obtain
indices of positive and negative symptoms. Parkinson’s disease severity
in patients with PD were assessed immediately after testing using the
Hoehn and Yahr (H&Y) rating scale (Hoehn and Yahr, 1967) and the
United Parkinson’s Disease Rating Scale (UPDRS) by a board certiﬁed
neurologist trained in administration and scoring.
2.3. Schizophrenia study design
Using a double-blind, within-subjects design, the study was divided
into two phases. To balance for potential practice effects due tomultipletesting, each patient was pseudo-randomly assigned to one of two
orders: 8 of 13 patients were ﬁrst assessed on PAL while receiving
antipsychotics followed by PAL during the administration of placebo
(the “on–off” group); the other 5 of 13 patients were administered
PAL assessment using the opposite treatment order (the “off–on”
group). Two patients with SC were non-compliant during the active
medication phase, leaving 11 SC patients in the active phase: four re-
ceived olanzapine, three received ziprasidone, one received risperidone,
one received clozapine, one received quetiapine fumarate, and one
received haloperidol. Antipsychotics were chosen based on availability
of placebo forms and after consultation between clinician and patient
concerning the antipsychotic to which each patient responded to best
in the past. During the inactive phase, all patients with SC were admin-
istered placebo and no adjunctives (with the majority, 85%, withdrawn
from second generation antipsychotics) and were “medication free” for
a period of between 3 and 4 weeks (whole sample mean = 25.0 days,
SD = 4.7; “on–off” group mean = 25.7 days, SD = 0.6; “off–on”
group mean = 25.4 days, SD = 5.7) before PAL assessment to allow
for antipsychotic “wash out.” The mean number of days between PAL
assessments in patients with SC was 80.5 days (SD = 42.5). Assess-
ments were made blind to the medication status of the patients. During
the active treatment phase patients with SC were “stabilized” on anti-
psychotics for approximately 12 weeks (whole sample mean =
82.3 days, SD = 42.4; “on–off” group mean = 70.3 days, SD = 17.9;
“off–on” group mean = 86.8 days, SD = 48.9) before PAL assessment.2.4. Parkinson’s disease study design
Using an open within-subjects design, the study was divided into
two phases. The design was counterbalanced in which four patients
with PDwere pseudo-randomly assigned to the on–off treatment condi-
tion while the remaining 3 patients with PD were pseudo-randomly
assigned to the off–on treatment condition. Seven patients with PD
were withdrawn from all dopamimetics (one patient with PD was
non-compliant during the off phase) for approximately 12 hours
(whole sample mean = 12.0 hours, SD = 1.5; “on–off” group mean =
12.0 hours, SD = 1.6; “off–on” group mean = 12.0 hours, SD = 1.7)
prior to PAL assessment. During the active phase, all patients with PD
were administered dopamimetics (primarily carbidopa/levodopa
combination with adjunctives such as pramipexole, pergolide, or
amantadine). Dopamimetic use was based on each patient’s personal
physician’s treatment of choice. The mean number of days between
PAL assessments in patients with PD was 3.6 days (SD = 4.2).2.5. PAL test and analyses
The procedure for PAL and analyses followed previous studies
(Knowlton et al., 1996a,b;Weickert et al., 2002, 2010). See Supplemental
Material for a detailed description of the PAL test, an example of the
probability structure of the test, and an example trial. Probability sched-
ules were reorganized at follow-up assessments to promote new learn-
ing of cue–outcome associations. A series of single sample t-tests were
performed separately for each group in each condition to determine
the extent to which learning improved signiﬁcantly above chance levels
of performance (i.e., above 50% correct). Given the relatively large num-
ber of comparisons performed overall (at every tenth trial for a total of
15 comparisons per group per condition), a conservative Bonferroni
correction for multiple comparisons was applied to the results such
that in order to be considered signiﬁcant, a p value would have to be
≤0.0006, which would equate to a corrected p value of ≤0.05. The
numbers of omissions during PAL in patient versus control groups
were compared in a separate series of t-tests and correlations between
symptom scores and PAL in both patient groups were assessed in each
condition.
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3.1. Demographics, psychotic symptoms, and PD severity ratings
See Table 1 for a summary of the mean age, education levels, and
symptom scores (on and off medications) for all participants. Partici-
pants with PD had a mean Hoehn & Yahr stage of illness score of 1.7
(SD = 0.5) and a levodopa equivalent daily dose (LED) of 545.0 mg
(SD = 229.4 mg). Separate independent t-tests revealed no signiﬁcant
difference between patients and their respective control groups on the
basis of age: SC versus young control (YC), t(22) = 0.25, p = 0.81; PD
versus elderly control (EC), t(14) = 0.45, p = 0.66. There was also no
signiﬁcant difference between the patients with PD and ECs on the
basis of education, t(13) = 1.03, p = 0.32. However, therewas a signif-
icant but expected difference between patients with SC and YCs on the
basis of education, t(24) = 2.96, p b 0.01.
3.2. Patients with SC and patients with PD on and off dopaminergic
medication and controls
A series of single sample t-tests performed separately for each group
in each condition to determine the extent to which learning improved
signiﬁcantly above chance levels of performance (i.e., above 50%correct)
revealed signiﬁcant improvement above chance levels during the later
trials in both young (after trial 30, see Fig. 1A) and elderly (after trial
60, see Fig. 1D) control groups; however, people with schizophrenia
on antipsychotics never improved signiﬁcantly above chance levels
(see Fig. 1C), while the same patients with schizophrenia off antipsy-
chotics improve signiﬁcantly above chance levels of performance after
trial 100 (see Fig. 1B); conversely, patients with Parkinson’s disease
fail to improve signiﬁcantly above chance levels under both conditions
(off and on dopamimetics) (see Fig. 1E and F). See Supplemental mate-
rial for the analysis of omissions during PAL in both patient groups rela-
tive to their control group and for the correlations between symptom
scores and PAL in both patient groups under each condition.
4. Discussion
These results demonstrate an effect of DA receptor signaling deple-
tion on PAL. Whether blocking dopamine receptor with antipsychotics
in SC or depleting presynaptic dopamine in PD, PAL is relatively im-
paired. When dopamine receptor signaling is enhanced, primarily by
removing dopamine blockade in SC, later aspects of PAL improve
(although restoring dopamine signaling in PD is insufﬁcient to yield
signiﬁcant improvement in PAL).
These results in PD are consistent with previous work (Knowlton et
al., 1996b; Shohamy et al., 2004a) showing impaired acquisition during
PAL in patients with PD receiving dopamimetics. Withdrawal from
dopamimetics in PD also adversely affects PAL as patients with PD off
dopamimetics did not signiﬁcantly improve above chance across all
trials. The present results donot support a recent study showing impaired
PAL in people with PD receiving dopamimetics relative to medication
withdrawal in which they improved (Jahanshahi et al., 2010). PatientsTable 1
Mean age, education level, PANSS, and UPDRS scores for patients with schizophrenia, Parki
N Age Education (years) PANS
Positi
Patients with schizophrenia 13 35.3 (9.8) 14.6 (2.5)⁎ 15.0 (
Healthy young adult participants 13 34.3 (9.6) 17.0 (1.5) —
Patients with Parkinson’s disease 8 61.1 (7.7) 16.9 (1.6) —
Healthy older adult participants 10 59.2 (9.2) 15.8 (2.4) —
Standard deviation in parentheses. PANSS = Positive and Negative Syndrome Scale; UPDR
⁎ Statistically signiﬁcant difference from healthy young adult participants at p b 0.01.in the Jahanshahi et al. (2010) study were more severely affected
(mean UPDRS of 18.0 on versus 36.3 off) compared to those in our
study (mean UPDRS of 9.5 on versus 16.7 off) and were receiving
higher doses of dopamimetics than those in our study (mean LED
821.4 mg versus 545.0 mg). Thus, increased dopamimetic dose and/
or more likely disease severity of patients in the previous study may
have negatively inﬂuenced learning.
Results from the current study in patients with SC receiving anti-
psychotics is consistent with earlier studies (Weickert et al., 2002;
Keri et al., 2005; Horan et al., 2008; Weickert et al., 2009), in which
patients with SC receiving antipsychotics show an overall impaired
performance relative to YCs. Patients with SC withdrawn from anti-
psychotics showed signiﬁcant improvement during the later trials
similar to signiﬁcant improvement during later trials in YCs although
the patients with SC withdrawn from antipsychotics improved signif-
icantly above chance much later than YCs (after trial 100 in SC as
opposed to after trial 30 in YCs). The result in the patients with SC with-
drawn from antipsychotics is consistent with an increase of dopamine
receptor activity yielding improved PAL during later trials when striatal
activity becomes relevant to PAL (Poldrack et al., 1999, 2001). Thus,
while removal of dopamine blockade often produces a worsening of
“positive” psychotic symptoms and cognition (Weickert et al., 2003),
antipsychotic withdrawal appears to improve PAL during later trials in
SC,whereas restoring antipsychotics impairs later PAL. However, studies
of ﬁrst episode psychosis and people at risk for psychosis (Buchsbaum et
al., 2007;Murray et al., 2008; Fusar-Poli et al., 2011) showabnormal cau-
date nucleus function and connectivity which suggests that frontal–
striatal dysfunction and the related PAL impairment during early trials
may be illness related.
Findings of PAL increases during increased dopamine receptor sig-
naling (off antipsychotics in SC) and an inability to improve PAL during
decreased dopamine receptor signaling (on antipsychotics in SC) corre-
sponds well with the extant literature on the inﬂuence of dopamine on
learning. Dopamine antagonists (reducing dopamine levels) disrupt the
reinforcing properties of numerous stimuli (Wise et al., 1978). Self ad-
ministration of amphetamine and cocaine (both dopamine agonists in-
creasing dopamine levels) is reinforcing in rodents (Pickens and Harris,
1968; Pickens and Thompson, 1968) and administration of amphet-
amine increases caudate nucleus and prefrontal cortex dopamine levels
in nonhuman primates (Saunders et al., 1994). Stimuli with reinforcing
properties elicit increased dopamine neuron activity in non-human
primates (Schultz et al., 1997) and increased ventral striatum/nucleus
accumbens activity in humans (Elliott et al., 2000; Knutson et al.,
2001; Morris et al., 2012).
Our study has some potential limitations. Although education
displayed a signiﬁcant difference between SC and YCs, Weickert et al.
(2002) demonstrated signiﬁcant PAL performance differences between
a subset of patients with SC and controls matched on education. An in-
dependent study (Weickert et al., 2010) also showed no relationship
between education and PAL in relatively large samples of SC and control
groups. In the present study, only weak tomildly strong, nonsigniﬁcant
correlations were obtained between education and PAL (see Supple-
mental material). Although patients with SC made signiﬁcantly morenson’s disease, and healthy adult participants.
S UPDRS
ve on Positive off Negative on Negative off On Off
3.3) 16.0 (4.6) 15.4 (6.0) 14.1 (3.2) — —
— — — — —
— — — 9.5 (2.0) 16.7 (2.4)
— — — — —
S = United Parkinson’s Disease Rating Scale (motor summary).
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Fig. 1. Acquisition (learning curves) during probabilistic association learning in patients with schizophrenia (SC) and patients with Parkinson’s disease (PD) on and off dopaminer-
gic medication, healthy young controls (YC), and elderly controls (EC) showing signiﬁcant improvement above chance levels of performance in each group and condition. YCs im-
prove signiﬁcantly above chance after trial 30 (A). Patients with SC off antipsychotics improve signiﬁcantly above chance after trial 100 (B). Patients with SC on antipsychotics fail to
improve signiﬁcantly above chance across 150 trials (C). ECs improve signiﬁcantly above chance after trial 60 (D). Patients with PD off (E) and on (F) dopamimetics fail to improve
signiﬁcantly above chance across 150 trials.±Standard error provided asmeasure of variance. * Signiﬁcant improvement above chance levels of performance after applying a conservative
Bonferroni correction for multiple comparisons such that in order to be considered signiﬁcant, a p value would have to be ≤0.0006, which equates to a corrected p value of ≤0.05.
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omissions on average relative to the total number of responses was low
(between 8% and 9%). While practice effects may have contributed to
improved PAL, improvement solely due to practice would seem unlikely
since the administration order was balancedwith respect to active treat-
ment versus placebo status. Patients within their diagnostic group were
receiving different medications which may also limit our interpretation.
Although the number of patients with PD was relatively small, these
patients clearly did not show improvement across all trials in either con-
dition andnever improved signiﬁcantly above chance or to control levels.
Finally, it is not clear whether the effects of being withdrawn from
dompaminergic treatments reported here generalize to all cognitive do-
mains. However, the patients with SC in this studywere also assessed on
other cognitive domains under both active and placebo conditions and
generally showed signiﬁcant impairment across all cognitive domains
following withdrawal from antipsychotics (Weickert et al., 2003). Thus,
with respect to SC, results from the present study appear to be unique
to PAL such that patients with SC withdrawn from antipsychotics display
signiﬁcant PAL improvement.
In summary, during a test of PAL, patients with PD withdrawn from
dopamimetics (representing a decrease in dopamine receptor signaling)
failed to demonstrate signiﬁcant improvement over 150 trials and pa-
tients with SC withdrawn from antipsychotics (representing an increase
in dopamine receptor signaling) displayed signiﬁcant improvement
above chance levels of performance during later trials similar to controls.
These results demonstrate that (1) dopamine replacement in PD is insuf-
ﬁcient to signiﬁcantly improve PAL and (2) the removal of dopamine
blockade by antipsychotics in SC signiﬁcantly improves PAL, which is a
novelﬁnding and is opposite to the effects of dopamine blockade removal
on other cognitive domains in SC.Role of funding source
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